Nasdaq · CIK 0001314052
AVXL ANAVEX LIFE SCIENCES CORP.
Insider trading from SEC Form 4. Last filing 15 d ago.
In brief
ANAVEX LIFE SCIENCES CORP. (AVXL) has 23 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 28, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at ANAVEX LIFE SCIENCES CORP., scored.
Transactions
Every row filed, 33 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | 15 d ago |
| Sep 24, 2026 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | 15 d ago |
| Sep 24, 2026 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | 15 d ago |
| Sep 24, 2026 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | 15 d ago |
| Jan 6, 2026 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Jan 9, 2026 |
| Jan 6, 2026 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jan 9, 2026 |
| Oct 2, 2025 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 250,000 | Oct 3, 2025 |
| Oct 2, 2025 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 25,000 | Oct 3, 2025 |
| Sep 11, 2025 | Christopher U Missling President and CEO | MOption exercise Common Stock | +187,500 | $5.04 | $945k | 1,655,213 | Sep 12, 2025 |
| Sep 11, 2025 | Christopher U Missling President and CEO | FTax withholding Common Stock | -145,048 | $9.58 | $1.4M | 1,510,165 | Sep 12, 2025 |
| Sep 11, 2025 | Christopher U Missling President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -187,500 | $0.00 | $0 | 0 | Sep 12, 2025 |
| Aug 20, 2025 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Aug 22, 2025 |
| Aug 20, 2025 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Aug 22, 2025 |
| Jun 5, 2025 | Steffen Thomas director | MOption exercise Common stock | +50,000 | $1.76 | $88k | 55,000 | Jun 9, 2025 |
| Jun 5, 2025 | Steffen Thomas director | FTax withholding Common stock | -11,349 | $7.75 | $88k | 43,651 | Jun 9, 2025 |
| Jun 5, 2025 | Steffen Thomas director | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Apr 28, 2025 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Apr 30, 2025 |
| Apr 28, 2025 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Apr 30, 2025 |
| Mar 31, 2025 | Claus Vander Velden director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 31, 2025 | Steffen Thomas director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 31, 2025 | Athanasios Skarpelos director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 31, 2025 | Jiong Ma director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 31, 2025 | Peter D.O. Donhauser director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
| Mar 24, 2025 | Christopher U Missling President and CEO | MOption exercise Common Stock | +500,000 | $0.92 | $460k | 1,750,210 | Mar 26, 2025 |
| Mar 24, 2025 | Christopher U Missling President and CEO | FTax withholding Common Stock | -282,497 | $9.63 | $2.7M | 1,467,713 | Mar 26, 2025 |
| Mar 24, 2025 | Christopher U Missling President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -500,000 | $0.00 | $0 | 0 | Mar 26, 2025 |
| Jan 15, 2025 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Jan 17, 2025 |
| Jan 15, 2025 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +166,666 | $0.00 | $0 | 166,000 | Jan 17, 2025 |
| Jan 15, 2025 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jan 17, 2025 |
| Dec 19, 2024 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Dec 23, 2024 |
| Dec 19, 2024 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | Dec 23, 2024 |
| Nov 19, 2024 | Sandra Boenisch PFO & Treasurer | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 20,000 | Dec 6, 2024 |
| Nov 19, 2024 | Christopher U Missling President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 250,000 | Dec 6, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sandra BoenischPFO & Treasurer
- Peter D.O. Donhauserdirector
- Christopher U MisslingPresident and CEO
- Jiong Madirector
- Athanasios Skarpelosdirector
- Steffen Thomasdirector
- Claus Vander Veldendirector
Questions about AVXL
Answered from the filings on this page, as of the latest one.
Are insiders buying AVXL?
No. In the last 90 days no insider at ANAVEX LIFE SCIENCES CORP. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AVXL on the open market?
No open-market trade has been scored at ANAVEX LIFE SCIENCES CORP.. The latest Form 4 on file was filed on Sep 28, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at ANAVEX LIFE SCIENCES CORP.?
7 people have filed a Form 4 at ANAVEX LIFE SCIENCES CORP., among them Sandra Boenisch (PFO & Treasurer), Peter D.O. Donhauser (director), Christopher U Missling (President and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.